These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23678600)

  • 21. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis.
    Tadokoro S; Okamura N; Sekine Y; Kanahara N; Hashimoto K; Iyo M
    Schizophr Bull; 2012 Sep; 38(5):1012-20. PubMed ID: 21402722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aripiprazole's receptor pharmacology and extrapyramidal side effects.
    Poyurovsky M; Weizman R; Weizman A
    Am J Psychiatry; 2008 Mar; 165(3):398; author reply 398-9. PubMed ID: 18316435
    [No Abstract]   [Full Text] [Related]  

  • 24. Aripiprazole-induced tardive dyskinesia: the role of tamoxifen.
    Evcimen YA; Evcimen H; Holland J
    Am J Psychiatry; 2007 Sep; 164(9):1436-7. PubMed ID: 17728431
    [No Abstract]   [Full Text] [Related]  

  • 25. Aripiprazole: a review of its pharmacology and clinical use.
    Taylor DM
    Int J Clin Pract; 2003; 57(1):49-54. PubMed ID: 12587943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats.
    Nordquist RE; Risterucci C; Moreau JL; von Kienlin M; Künnecke B; Maco M; Freichel C; Riemer C; Spooren W
    Neuropharmacology; 2008 Feb; 54(2):405-16. PubMed ID: 18054053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
    Costentin J
    Encephale; 2009 Feb; 35(1):66-72. PubMed ID: 19250996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro.
    Kato T; Mizoguchi Y; Monji A; Horikawa H; Suzuki SO; Seki Y; Iwaki T; Hashioka S; Kanba S
    J Neurochem; 2008 Jul; 106(2):815-25. PubMed ID: 18429930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
    Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
    Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperprolactinemia with aripiprazole: understanding the paradox.
    Saraf G; Behere RV; Venkatasubramanian G; Rao NP; Varambally S; Gangadhar BN
    Am J Ther; 2014; 21(3):e80-1. PubMed ID: 22357167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?
    DeQuardo JR
    J Clin Psychiatry; 2004 Jan; 65(1):132-3. PubMed ID: 14976671
    [No Abstract]   [Full Text] [Related]  

  • 32. Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic.
    Buckley PF
    Drugs Today (Barc); 2003 Feb; 39(2):145-51. PubMed ID: 12698209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
    Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
    CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistent hiccups associated with switching from risperidone to aripiprazole in a schizophrenic patient with cerebral palsy.
    Yeh YW
    Clin Neuropharmacol; 2011; 34(4):135-6. PubMed ID: 21768798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical impact of aripiprazole in patients suffering from schizophrenia].
    Levoyer D; Drapier D; Fadier-Salicé G; Millet B
    Encephale; 2007; 33(3 Pt 1):332-8. PubMed ID: 17675931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism.
    Naber D; Lambert M
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1213-9. PubMed ID: 15588748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Aripiprazole use in children and adolescent psychiatric patients].
    Chevreuil C; Polard E; Lemonnier E; Guillemot P; Bentué-Ferrer D;
    Therapie; 2011; 66(2):123-30. PubMed ID: 21635859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
    Broekhof R; Gosselink MJ; Pijl H; Giltay EJ
    Gen Hosp Psychiatry; 2012; 34(2):209.e1-3. PubMed ID: 21872335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.